Abstract Number: PB1808
Meeting: ISTH 2020 Congress
Background: Patients with Chronic myeloproliferative neoplasms (MPN) present at the onset or during evolution thrombotic complications.
Aims: We retrospectively analysed the platelet membrane parameter and correlation with treatment outcome, thrombosis events in order to identify characteristics of platelet function in patients with MPN especially in those with high thrombotic risk.
Methods: This retrospective study included 150 patients with MPN as well as 15 healthy volunteers. The diagnosis of MPN was made according to World Health Organization (WHO) classification of MPNs. We evaluated the flow cytometry markers of platelet adhesion (CD42a, CD42b), aggregation (CD41, CD61) and CD36. Production of reactive species (ROS) was examined using fluorescence method with DCFDA and was assessed by aria under curve (AUC) in serial measurements during 900 sec. The determination of platelet membrane potential was done by fluorescence method using 3,3′-dipropyl-2,2′-thiadicarbocyanine iodide (DiSC3-5)
Results: The ROS production is significantly higher in MPN group, p= 0.04. Patients in advanced phase of myeloid metaplasia (grade 5 Hackett of splenomegaly) has high level of ROS production compared with patients diagnosed in early stage (grade 1 or 2 Hackett of splenomegaly) median value: 13178014970 vs 12303298585, p=0.001. There are no differences between groups that was splitted by type of treatment Ruxolitinib/Hydroxiureea or type of mutation diagnosed JAK2V617F/CALR/no mutation. Patients with MPN present higher resting membrane potential (RMP) compared with controls (median value – 63 mV vs – 57.5mV, p=0.05). The expression of CD36 receptor was higher in MPN group vs controlsp=0.003. here are significant correlation between resting membrane potential and expression of CD42b (r -0.45, p=0.04) and GlyA receptors (r -0.45, p=0.04).
Conclusions: Patients with MPN especially those with have a higher level ono reports are regarding platelet membrane. It was proved that generation of intracellular ROS is associated with CD36 signaling and represent one start point for thrombosis.
To cite this abstract in AMA style:Popov V, Matei CO, Andreescu M, Moisescu MG, Savopol T. The Assessment of Platelet Membrane Alteration in Patients with Chronic Myeloproliferative Neoplasms [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/the-assessment-of-platelet-membrane-alteration-in-patients-with-chronic-myeloproliferative-neoplasms/. Accessed January 21, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-assessment-of-platelet-membrane-alteration-in-patients-with-chronic-myeloproliferative-neoplasms/